Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Eur Heart J
; 44(5): 396-407, 2023 02 01.
Article
in En
| MEDLINE
| ID: mdl-36478225
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sodium-Glucose Transporter 2 Inhibitors
/
Heart Failure
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Eur Heart J
Year:
2023
Type:
Article
Affiliation country:
Germany